|
Light at the End of the Telecom Tunnel
Technology Op-Ed
7.30.2004
After years of struggling under a massive regulatory framework, the telecommunications industry is starting to see some positive change. Last week, the National Conference of State Legislatures (NCSL) admitted that current regulations stifle innovation, and today the American Legislative Exchange Council (ALEC) will consider a similar policy statement.
Read more
|
|
|
Wal-Mart's Principles
Business and Economics Op-Ed
By: Sally C. Pipes
7.29.2004
Barbara Ehrenreich (''Wal-Mars Invades Earth,'' column, July 25) suggests that Wal-Mart's growth is somehow other-worldly. It is not. Instead, it is solidly grounded in economic principles understood worldwide.
Read more
|
|
|
'No Child' calls for better testing method
Education Op-Ed
By: Lance T. Izumi, J.D.
7.29.2004
Your July 13 article, "School-choice advocates launch awareness campaign," showed how the federal No Child Left Behind law has given Indiana families a number of options to deal with problematic schools. Underperforming students now have access to free tutoring, or they can transfer to a better-performing school.
Read more
|
|
|
Want To Bet on the Presidential Election?
Technology Op-Ed
7.26.2004
In just a few short months, Americans will decide who they want to be president. Speculation abounds, but a better read on who is more likely to win -- a futures market in politics -- may be found at sites like Tradesports.com.
Read more
|
|
|
Commentary: States Undercutting Student Proficiency Drive
Education Op-Ed
By: Lance T. Izumi, J.D.
7.25.2004
Imagine two students. Billy, who lives in an affluent suburb and attends a highly regarded public elementary school, is an average-performing pupil whose reading and math test results are just below the state's definition of proficiency in those subjects. Maria, who lives in a low-income neighborhood and attends a problem-plagued public elementary school, performs very poorly on state tests and is nowhere near the proficient level.
Read more
|
|
|
Jaundiced View Excludes Idea of Charitable Acts
Health Care Op-Ed
By: Sally C. Pipes
7.23.2004
Sir, In her seething column "Big pharma is a two-faced friend" (July 19), Marcia Angell is furious at Pfizer for giving discount drugs to uninsured Americans. Apparently, offering cheaper drugs to low-income people is nothing but a cynical public relations ploy by the pharmaceutical industry.
Read more
|
|
|
Freeing the Telcos
PRI in the News
7.21.2004
Perhaps deregulation finally is ready to turbocharge telecommunications. One of the more striking advances will come in October to Huntington Beach, when the city will become one of three cities nationwide where the telephone company Verizon will begin equipping homes with a new high-speed fiber-optic network. The other two cities are in as-yet-undisclosed areas of San Bernardino and Riverside counties.
Read more
|
|
|
Privacy: Real estate's Achilles Heel (Part 1)
PRI in the News
By: Jessica Swesey
7.21.2004
Editor's note: Privacy and real estate are intertwined in many ways. This three-part series explores the Patriot Act and its impact on real estate companies, what the industry is doing about privacy compliance, and how realty professionals are protecting their buisnesses and clients.
Read more
|
|
|
Wal-Mart suit uses bad logic
Business and Economics Op-Ed
By: Sally C. Pipes
7.19.2004
On June 22 in San Francisco, U.S. District Judge Martin Jenkins granted class-action status for a suit charging that Wal-Mart discriminates against women. That is a huge escalation, changing it from a case involving seven women to 1.6 million current and former employees, the largest class action on record. This is what the plaintiffs' attorneys wanted, but the case is far from over.
Read more
|
|
|
Government Oversight and Protecting VoIP
Technology Op-Ed
7.15.2004
The Senate Commerce Committee will soon vote on a bill to bar states from meddling with Voice over Internet Protocol (VoIP), which allows the Internet to be used like a telephone.
Read more
|
|
|
Outsourcing and Protectionist Rhetoric in the Senate
Technology Op-Ed
7.9.2004
When old ideas meet new technology, the result is sometimes a comedy of errors. Such is the case for New York Senator Hillary Clinton, whose outdated thinking produced many a blunder. On one recent occasion, she played the protectionist card on the issue of outsourcing and got caught in her own hypocrisy.
Read more
|
|
|
The Valley Edge
Technology Op-Ed
7.9.2004
In preparation for the Presidential election in November, a group of Silicon Valley's most influential entrepreneurs gathered in Redwood City to hash out the pros and cons of George Bush verses John Kerry. The debate, heated at times, revealed an ongoing dilemma.
Read more
|
|
|
Digital Battleground: From Congress to the Marketplace
Technology Op-Ed
7.2.2004
The battle between Hollywood and Silicon Valley over copyright issues heated up recently as two bills in Congress generated attention. Each side has a point, but consumers would be better off if the battleground were the marketplace, not the political stage.
Read more
|
|
|
Cut and Run: California Retreats On Math
Education Op-Ed
By: Lance T. Izumi, J.D.
7.1.2004
The controversy over American jobs going overseas has so far largely overlooked a key factor: poor-quality American education. American companies, faced with a domestic labor pool deficient in even basic knowledge and skills, are financing the math and science education of students in foreign countries. Yet, despite the implications of this trend, California has reduced the difficulty of math requirements for students.
Read more
|
|
|
Saying No to Foreign Drugs
Health Care Op-Ed
By: Sally C. Pipes
7.1.2004
In this season of the campaign promises, pandering, and appeals to high principle, let's be candid: The process of wealth redistribution through the institutions of democratic politics combines all three beautifully. The latest manifestation of this art form is the current drive in Congress to facilitate the importation of "cheap" pharmaceuticals into the U.S. from Canada (and a number of other nations). This will purportedly reduce U.S. drug costs sharply, with no adverse effects upon future drug development or safety.
Read more
|
|
|
